A199730 logo

BioInfra Co., Ltd. Stock Price

KOSDAQ:A199730 Community·₩20.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A199730 Share Price Performance

₩4,180.00
-2050.00 (-32.91%)
₩4,180.00
-2050.00 (-32.91%)
Price ₩4,180.00

A199730 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

2 Risks
0 Rewards

BioInfra Co., Ltd. Key Details

₩23.1b

Revenue

₩17.9b

Cost of Revenue

₩5.2b

Gross Profit

₩14.4b

Other Expenses

-₩9.1b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.88k
22.59%
-39.45%
64.9%
View Full Analysis

About A199730

Founded
2007
Employees
n/a
CEO
Sangdeuk Lee
WebsiteView website
www.bioinfrakorea.co.kr

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances. The company was founded in 2007 and is based in Yongin-si, South Korea.

Recent A199730 News & Updates

BioInfra Co., Ltd.'s (KOSDAQ:199730) Share Price Is Matching Sentiment Around Its Revenues

Jan 08
BioInfra Co., Ltd.'s (KOSDAQ:199730) Share Price Is Matching Sentiment Around Its Revenues

Recent updates

No updates